ARIE BELLDEGRUN, MD
Urology in Los Angeles, CA
License number
California A44477
Category
Radiology
Type
Urology
Address
Address
200 Medical Plz SUITE 140, Los Angeles, CA 90095
Phone
(310) 794-7700
(310) 301-8751 (Fax)
(310) 301-8751 (Fax)
Organization information
See more information about ARIE BELLDEGRUN at bizstanding.comArie Belldegrun MD
200 Ucla Medical Plz, Los Angeles, CA 90095
Industry:
Urologist
Phone:
(310) 794-7700 (Phone)
Arie Shlomo Belldegrun
Arie Belldegrun MD
10833 Le Conte Ave, Los Angeles, CA 90095
Categories:
General Surgeons, Urology Physicians & Surgeons
Phone:
(310) 206-1434 (Phone)
Arie Belldegrun MD
924 Westwood Blvd, Los Angeles, CA 90024
Industry:
Medical Doctor's Office
Medical Doctor:
Arie Belldegrun (Medical Doctor)
ARIE BELLDEGRUN, M.D., INC
811 Strada Vecchia, Los Angeles, CA 90077
Registration:
Oct 21, 1992
State ID:
C1845738
Business type:
Articles of Incorporation
President:
Arie Belldegrun (President)
Professional information
Nucleic Acid Molecules Comprising The Prostate Specific Antigen (Psa) Promoter And Uses Thereof
US Patent:
5919652, Jul 6, 1999
Filed:
Sep 1, 1995
Appl. No.:
8/522841
Inventors:
Shen Pang - Van Nuys CA
Arie S. Belldegrun - Los Angeles CA
Arie S. Belldegrun - Los Angeles CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C12P 2100, C12N 1585, C12N 510, C07H 2104
US Classification:
435 691
Abstract:
The present invention provides isolated or purified nucleic acid molecules comprising a prostate specific antigen (PSA) promoter alone or in combination with a cytomegalovirus (CMV) promoter.
Arie S Belldegrun, Los Angeles CA
Specialties:
Urology, Surgical Oncology
Work:
Patient Clinic
200 Ucla Medical Plz, Los Angeles, CA 90095
200 Ucla Medical Plz, Los Angeles, CA 90095
Education:
Hebrew University, Hadassah Medical School (1975)
Arie S Belldegrun, Los Angeles CA
Specialties:
Urologist
Address:
10833 Le Conte Ave, Los Angeles, CA 90095
Board certifications:
American Board of Urology Certification in Urology
Chimeric Transcriptional Regulatory Element Compositions And Methods For Increasing Prostate-Targeted Gene Expression
US Patent:
7267978, Sep 11, 2007
Filed:
Oct 13, 2000
Appl. No.:
10/110681
Inventors:
Michael F. Carey - Sherman Oaks CA, US
Arie S. Belldegrun - Los Angeles CA, US
Lilly Wu - Northridge CA, US
Arie S. Belldegrun - Los Angeles CA, US
Lilly Wu - Northridge CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C12N 15/00
US Classification:
4353201
Abstract:
Disclosed are compositions and methods for achieving successful treatment of disorders of the human prostate. In preferred embodiments, methods and compositions are provided that improve the specificity and safety of gene delivery vectors, and improve the prostate-specificity and activity of genetic constructs targeted for prostate-specific expression. Also disclosed are methods utilizing a variety of therapeutic genes, including those encoding tumor-specific therapeutics, e. g. , TRAIL, tumor suppressors, cytotoxins, and the like, for the treatment of proliferative disorders of the prostate, and in particular, prostatic hyperplasia, prostate cancer and prostatic tumors. In preferred embodiments genetic constructs are disclosed comprising one or more prostate-specific chimeric enhancer elements in combination with one or more wildtype core enhancer elements and a prostate-specific proximal promoter that increase expression of selected heterologous genes operably positioned under their control.
Ca9 Gene Single Nucleotide Polymorphisms Predict Prognosis And Treatment Response Of Metastatic Renal Cell Carcinoma
US Patent:
2011026, Oct 27, 2011
Filed:
Oct 8, 2009
Appl. No.:
13/122553
Inventors:
Arie S. Belldegrun - Los Angeles CA, US
Allan J. Pantuck - Los Angeles CA, US
Allan J. Pantuck - Los Angeles CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 38/20, A61P 35/04, A61P 35/00, A61P 37/04, C12Q 1/68, C07H 21/04
US Classification:
424 852, 435 611, 536 2431
Abstract:
Methods and compositions for providing a prognosis or diagnosis for a human patient having renal cell cancer are provided. The method relates to the discovery of SNPs which are associated with a favorable prognosis and response to therapy in RCC.
Kidney-Specific Tumor Vaccine Directed Against Kidney Tumor Antigen G-250
US Patent:
7572891, Aug 11, 2009
Filed:
Feb 13, 2001
Appl. No.:
09/783708
Inventors:
Arie Belldegrun - Los Angeles CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C07K 14/52
US Classification:
530351
Abstract:
This invention provides an anti-cancer immunogenic agent(s) (e. g. vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a G250 antigenic marker. Preferred immunogenic agents comprise a chimeric molecule comprising a kidney cancer specific antigen (G250) attached to a granulocyte-macrophage colony stimulating factor (GM-CSF). The agents are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.
Fusion Molecule Based On Novel Taa Variant
US Patent:
2013023, Sep 5, 2013
Filed:
Jan 11, 2013
Appl. No.:
13/740099
Inventors:
Arie Belldegrun - Los Angeles CA, US
Assignee:
The Regents of the University of California - Los Angeles CA
International Classification:
C12N 9/96
US Classification:
424 851, 435188, 4353201, 604522
Abstract:
This invention provides novel carbonic anhydrase (CAIX) nucleic acid and peptide sequences, as well as related methods and compositions, including anti-cancer immunogenic agent(s) (e.g. vaccines and chimeric molecules) that elicit an immune response specifically directed against cancer cells expressing a CAIX antigenic marker. The novel CAIX variant and related compositions are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, adoptive immunotherapy.
Fusion Molecule Based On Novel Taa Variant
US Patent:
8378084, Feb 19, 2013
Filed:
Dec 21, 2007
Appl. No.:
12/520084
Inventors:
Zhenhua Li - Los Angeles CA, US
Arie S. Belldegrun - Los Angeles CA, US
Arie S. Belldegrun - Los Angeles CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C07H 21/00, C07K 14/00, C12N 5/10, C12N 15/09, C12N 15/74
US Classification:
536 231, 536 234, 514 44 R, 530350, 4241841, 435 723, 435 693, 435325, 4353201
Abstract:
This invention provides novel carbonic anhydrase (CAIX) nucleic acid and peptide sequences, as well as related methods and compositions, including anti-cancer immunogenic agent(s) (e. g. vaccines and chimeric molecules) that elicit an immune response specifically directed against cancer cells expressing a CAIX antigenic marker. The novel CAIX variant and related compositions are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.
Psa Positive Regulating (Psar) Sequences And Uses Thereof
US Patent:
6110702, Aug 29, 2000
Filed:
Mar 27, 1997
Appl. No.:
8/828972
Inventors:
Shen Pang - Van Nuys CA
Arie S. Belldegrun - Los Angeles CA
Arie S. Belldegrun - Los Angeles CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C12P 2106, C12P 2104, C12N 1500, C07H 2104
US Classification:
435 691
Abstract:
The present invention provides an isolated nucleic acid molecule which is a PSA positive regulatory sequence (PSAR). This molecule has been deposited with the ATCC. In one embodiment of the invention, the molecule comprises a nucleic acid sequence shown in FIG. 4 (SEQ ID NO: 3).
Methods Of Renal Cell Carcinoma Prognosis And Treatment Selection With Carbonic Anhydrase Ix
US Patent:
2005015, Jul 21, 2005
Filed:
Apr 15, 2003
Appl. No.:
10/511465
Inventors:
Matthew Bui - Los Angeles CA, US
David Seligson - Los Angeles CA, US
Arie Belldegrun - Los Angeles CA, US
David Seligson - Los Angeles CA, US
Arie Belldegrun - Los Angeles CA, US
International Classification:
G01N033/574
US Classification:
435007230
Abstract:
The present invention provides methods of aiding in a renal cell carcinoma prognosis that include quantifying expressed carbonic anhydrase in samples derived from renal cell carcinoma patients. The methods also identify patients that are likely to respond positively to selected courses of treatment. The invention further provides related computer program products.